Home > Oncology > ASCO GU 2022 > Urothelial Carcinoma > Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma

Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma

Presented By
Prof. Marc-Oliver Grimm, University Hospital Jena, Germany

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 2, TITAN-TCC
In patients with metastatic urothelial carcinoma who completed platinum-based chemotherapy, treatment with nivolumab and a nivolumab/ipilimumab boost significantly improved ORR compared with nivolumab monotherapy. This was demonstrated in the phase 2 TITAN-TCC trial. Nivolumab is an approved treatment after platinum-based chemotherapy in metastatic urothelial carcinoma [1]. The phase 2 TITAN-TCC trial (NCT03219775) was designed to evaluate a nivolumab/ipilimumab boost for patients who do not respond to 4 cycles of nivolumab. The primary endpoint was confirmed objective response rate (ORR) 30 weeks after the start of second-line nivolumab. Prof. Marc-Oliver Grimm (University Hospital Jena, Germany) presented the results [2]. The trial enrolled 83 patients, of whom 33 (16%) patients had stable disease and 31 (37%) patients had progressive disease after 4 dose...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on